High-dose tamoxifen enhances etoposide effectiveness in cancer treatment
Author Information
Author(s): N.S.A. Stuart, P. Philip, A.L. Harris, K. Tonkin, S. Houlbrook, J. Kirk, E.A. Lien, J. Carmichael
Primary Institution: ICRF Clinical Oncology Unit, Churchill Hospital, Oxford
Hypothesis
Can high-dose tamoxifen enhance the cytotoxicity of etoposide in patients with drug-resistant cancer?
Conclusion
High-dose tamoxifen can be administered with acceptable toxicity but does not significantly enhance etoposide cytotoxicity in vitro.
Supporting Evidence
- Two patients showed a partial response to the treatment.
- Significant nausea was reported in a portion of the patients.
- Serum levels of tamoxifen were sufficient to modulate drug resistance in vitro.
Takeaway
Doctors tested a combination of high-dose tamoxifen and etoposide on cancer patients, but it didn't work as well as hoped.
Methodology
Patients with relapsed or drug-resistant cancer were treated with oral etoposide and high-dose oral tamoxifen, followed by assessments of serum levels and toxicity.
Potential Biases
Potential bias due to lack of a control group and the subjective nature of reported symptoms.
Limitations
The study was small and primarily focused on safety rather than efficacy.
Participant Demographics
Median age was 50, with a mix of male and female patients and various cancer types.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website